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Beneficial Autoimmunity to Proinflammatory
Mediators Restrains the Consequences
of Self-Destructive Immunity
bodies to the C-C chemokine, MIP-1, to suppress ex-
perimental autoimmune encephalomyelitis (EAE) (Kar-
pus et al., 1995). Subsequently, Gong et al. suppressed
experimentally induced arthritis using an antagonist to
another C-C chemokine, MCP-1 (Gong et al., 1997).
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We have explored the use of naked DNA vaccinationIsrael
in order to induce a beneficial autoimmune response2 B Shine Department of Rheumatology
against endogenous proinflammatory mediators, in theRambam Medical Centre
context of two different autoimmune diseases: EAE, aHaifa 31096
model for multiple sclerosis (MS), and adjuvant-inducedIsrael
arthritis (AA), a model for RA (Wekerle et al., 1994). Our3 Rappaport Family Institute for Research in the
approach entails immunization with a mammalian ex-Medical Sciences
pression vector, encoding a selected proinflammatoryP.O. Box 9697
cytokine or chemokine, under the control of a strongHaifa 31096
viral promoter (CMV). The same vector also drives theIsrael
expression of bacterial CpG as a recurring immunostim-
ulatory sequence (ISS) (Raz et al., 1996; Sato et al.,
1996), which signals via TOLL receptor 9 (Finotto et al.,Summary
2002; Wen-Ming et al., 2000), triggering a breakdown of
tolerance and establishing an immune response againstTherapies that neutralize the function of TNF- sup-
gene products encoded by the vaccines. We demon-press rheumatoid arthritis (RA) but not osteoarthritis
strated that “vaccination” via administration of plasmid(OA). We show that patients suffering from RA but not
DNA constructs encoding various C-C chemokines fol-OA have significant levels of autoantibodies directed
lowed by later induction of EAE elicited antibody pro-to TNF-. Thus, the immune system can selectively
duction against the chemokines, which were encodedgenerate autoimmunity to proinflammatory mediators
by these genes used for “vaccination,” and at the samewhen such a response is beneficial for the host. A well-
time suppressed the disease (Youssef et al., 1998). Che-defined model of RA was used to elaborate the contri-
mokine-specific purified antibodies isolated from thesebution of beneficial autoimmunity to the regulation of
protected animals could then be used to transfer thedisease. We show that during the disease autoanti-
beneficial effects of each vaccine (Youssef et al., 1998).body production is elicited against few inflammatory,
Later, we showed that this strategy could be used tobut not regulatory, mediators. Selective amplification
rapidly treat ongoing autoimmunity and that neutraliz-of these beneficial antibodies by targeted DNA vac-
ing antibodies generated in response to the gene prod-cines provided protective immunity. Epitope mapping
uct of each vaccine can adoptively transfer the highrevealed that anti-TNF- immunity is highly restricted
state of resistance (Salomon et al., 2002; Wildbaum andand excretes no crossreactivity to other known gene
Karin, 1999; Wildbaum et al., 2002a, 2000b; Youssef etproducts. Its selective exclusion substantially exacer-
al., 2000, 1998).bated the disease. Administration of anti-TNF- anti-
Throughout these studies, we have repeatedly ob-bodies could then override this aggravation. This sub-
served some unexpected phenomena. The elicitation ofstantiates the significance of beneficial autoimmunity
beneficial autoantibody production was dependent onin restraining self-destructive immunity.
induction of an autoimmune disease and was regulated
by the immune system in accordance with disease pro-
Introduction gression. Thus, autoantibody production against the
vaccine-encoded product regressed to baseline levels
T cell-mediated autoimmune diseases result from a shortly after remission in acute EAE, whereas in chronic
breakdown of tolerance to self-components such as AA these antibodies were continuously produced, at a
myelin proteins in multiple sclerosis, -islets compo- very high titer (Salomon et al., 2002; Wildbaum and Karin,
nents in type I diabetes, or cartilage in rheumatoid arthri- 1999; Wildbaum et al., 2002a, 2000b; Youssef et al.,
tis (RA). In all of these diseases, proinflammatory cyto- 2000, 1998). Moreover, therapy of ongoing diseases led
kines and chemokines are believed to play a pivotal role to a very rapid (within less than 48 hr) production of
in the attraction of leukocytes to the site of autoimmunity highly specific beneficial autoantibodies (IgG2a) that
and in the initiation and progression of the inflammatory could effectively transfer disease resistance (Salomon
process. Thus, proinflammatory cytokines and chemo- et al., 2002; Wildbaum and Karin, 1999; Wildbaum et al.,
kines and their receptors constitute an important target 2002a, 2000b; Youssef et al., 2000, 1998). The most
for therapeutic intervention (Feldmann et al., 1996; Hu- reasonable explanation for these unexpected findings
ang et al., 2000; Izikson et al., 2000; Wildbaum et al., is that targeted DNA vaccines amplify a preexisting anti-
1998). Karpus and colleagues first demonstrated the self-regulatory response, which, by itself, is capable of
critical role of chemokines in autoimmunity, using anti- limiting, albeit not preventing, the emerging autoimmune
condition. The current study uses a variety of comple-
mentary strategies to explore this hypothesis.*Correspondence: nkarin@tx.technion.ac.il
Immunity
680
Figure 1. Beneficial Autoimmunity to Proin-
flammatory but Not Regulatory Mediators
Participates in the Regulation of AA
(A) Lewis rats were immunized with CFA to
induce active AA and separated into 14
groups of three rats each. On days 17 and
19, they were injected with plasmid DNA en-
coding MIP-1, MIF, IP-10, MCP-1, TNF-,
IL-15, IL-17, IFN-, IL-4, IL-10, IL-18BP, or
FasL. Sera were collected on day 22, and the
development of antibody titer to the relevant
gene product of each vaccine was deter-
mined, as described in Experimental Proce-
dures, in vaccinated (black bars) or control
AA rats (gray bars). These titers were also
recorded in sera of rats immunized with CFA
to hind footpads for the induction of a local
inflammatory response rather than poly-
arthritis (striped bars) and in sera from naive
rats (white bars). Results are shown as the
mean of three samples  SE.
(B) A group of Lewis rats was subjected to
active induction of AA. On day 17, the rats
were divided into seven groups of nine
equally sick rats and subjected to the admin-
istration of naked DNA vaccines (days 17 and
19, 300 g/rat) using DNA constructs encod-
ing MIF (open circles), IP-10 (filled diamonds),
TNF- (filled circles), IL-15 (filled triangles), or
IL-17 (open triangles), as described (Wild-
baum et al., 2000b). Control groups were
injected with a plasmid DNA construct en-
coding soluble intracellular -actin (filled
squares) (Wildbaum et al., 2000b) or were not
treated (open squares). The clinical manifes-
tations of disease were monitored by an ob-
server blind to the experimental protocol as
described before (Wildbaum et al., 2000b).
Clinical scores were also histologically veri-
fied (not shown). Results are shown as the
mean score of nine rats  SE.
(C) AA rats were subjected to plasmid DNA
therapy as in Figure 1B (days 17 and 19, 300
g/rat). Each group included 30 rats. On day 22, all rats were sacrificed and blood sera were purified in two steps: first on an IgG purification
column and then on CNBr columns loaded with the gene product of each vaccine. Each purified antibody was adoptively transferred to AA
rats (100 g/rat every other day beginning at the onset of disease) as follows: anti-MIF (open circles), anti-IP-10 (filled diamonds), anti-TNF-
(filled circles), anti-IL-15 (filled triangles), or anti-IL-17 (open triangles). Control rats were injected with IgG purified from -actin plasmid-
vaccinated rats (filled squares), or from untreated rats (open squares). An observer blind to the experimental protocol monitored the clinical
manifestations of the disease. Results are shown as the mean score of six rats  SE.
Results remained at baseline levels (log2Ab titer of 5–6). Plasmid
DNA vaccines encoding proinflammatory mediators
could not elicit anti-self responses under these condi-Beneficial Autoimmunity to Proinflammatory
but Not Regulatory Mediators Participates tions (log2Ab titer of 5–6 sera to all cytokines/chemo-
kines). These data imply that DNA vaccines encodingin the Regulation of AA
We followed the development of autoantibody produc- self-proinflammatory mediators can rapidly amplify but
not generate autoantibody responses.tion to various proinflammatory and regulatory media-
tors during AA and the ability of targeted DNA vaccines Following base of the tail immunization of heat-killed
Mycobacterium tuberculosis emulsified in oil, Lewis ratsto amplify each potential response (Figure 1). We show
that during the course of adjuvant arthritis, there are develop a long-term form of polyarthritis in all limbs,
whereas the administration of the same adjuvant to foot-autoantibody responses only to proinflammatory media-
tors including: MIP-1, MIF, IP-10, MCP-1, TNF-, IL- pads leads to a local DTH response (Pearson, 1956). To
determine whether elicitation of a high antibody titer to15, and IL-17 (Figure 1A, log2Ab titer of 14.3  0.26,
16  0.45, 14.3  0.26, 13  0.45, 16  0.45, 14.3  proinflammatory mediators could be associated with
the development of the autoimmune condition, we have0.26, and 14.3 0.26, respectively, compared to control
sera from naive donors: log2Ab titer of 6.6  0.26, 6.6  compared titers that developed in AA rats to those ap-
pearing following immunization of CFA in hind footpads.0.26, 6  0, 6.6  0.26, 6.6  0.26, 6.6  0.26, and 6 
0, p0.01 for each reciprocal comparison). The baseline The respective Ab titers in AA rats were significantly
higher than the corresponding titer in rats immunizedtiter of naive rats to each of the detected gene products
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with CFA in hind footpads (p  0.05). AA rats never matory cytokine has been preferentially selected be-
cause of its key function not only in experimental modelsmounted a notable response (over background of log2Ab
titer  6) against regulatory cytokines such as IL-10, of autoimmunity, but also in human RA (Arend et al.,
1994; Choy et al., 2002; Feldmann et al., 1997). At first,IL18 binding protein (IL-18BP), and IL-4 (Figure 1A). Even
the response to IFN- that plays a pleiotropic role in we mapped determinant that autoantibodies from AA
rats, which were or were not subjected to a TNF- en-the regulation of autoimmunity (Krakowski and Owens,
1996) was at background levels. Moreover, the immune coding DNA vaccine, bind on TNF- (Figure 2A). Autoan-
tibodies produced in AA rats bound only 3 out of 24response was different toward two members of the
same gene family: TNF-, a key proinflammatory media- different fragments that were constructed from the whole
cytokine (Figure 2A): Fragment 6 (p145–160, GQGCPDYtor, and Fas-L, that plays a dual role in the regulation
of autoimmunity (Suvannavejh et al., 2000; Wildbaum et VLLTHTVSR), Fragment 8 (p207–218, GDLLSAEVNLPK),
and Fragment 11 (p161–176, FAISYQEKVSLLSAIR). Tar-al., 2000a). An autoantibody response against TNF-
but not Fas-L was observed (Figure 1A). geted DNA vaccine encoding TNF- amplified only the
response to these 3 fragments (Figure 2A). The se-
quence of each peptide fragment was analyzed in theDNA Vaccination to Proinflammatory Cytokines
Protein Data Bank (ENTREZ), and we could not find anySuppressed Ongoing Arthritis
matching sequence to each of these fragments in anyAdministration of plasmid DNA vaccines encoding each
known protein (except for TNF-). This demonstratesproinflammatory mediator, during an ongoing disease,
the selective breakdown of tolerance against self andcould very rapidly accelerate autoantibody production
also implies that DNA vaccines indeed amplify a re-to each mediator (Figure 1A, p 0.01 for each compari-
sponse initiated by the disease itself. It should be noted,son). At the same time, these DNA vaccines suppressed
however, that using this procedure one could recordongoing disease (Figure 1B, Mean Max score of 13.2 
only binding to linear fragments and that potential con-1 and 14  0.8 in control groups versus 4  0.5, 4.8 
formational epitopes are being excluded. Western blot0.6, 6.5  0.9, 6  0.9, and 4.5  0.8 in rats treated with
analysis was then conducted to further corroborate theplasmid DNA encoding TNF-, MIF, IL-15, IL-17, or IP-
specificity of DNA vaccine-based anti-TNF- antibod-10, p  0.01, respectively). Vaccinating AA rats with an
ies. Figure 2B indicates that these antibodies are indeedempty vector did not lead to a significant amplification
highly specific for TNF- and do not bind to other mem-of Ab titer against each proinflammatory gene product
bers of the TNF family including TRANCE and Fas L.beyond the one caused by the disease itself (data not
They also do not bind other proinflammatory mediatorsshown). These results are consistent with our previous
such as IL-18 or MIP-1.publications (Salomon et al., 2002; Wildbaum and Karin,
1999; Wildbaum et al., 2002a, 2000b; Youssef et al.,
2000, 1998). Selective Exclusion of Anti-TNF- Immunity
Aggravates the Course of AA
Immunization with DNA Vaccine Is Highly Specific The contribution of anti-TNF- Ab produced during nat-
We checked whether the administration of a DNA vac- ural regulation of disease was then evaluated by com-
cine encoding one inflammatory mediator might induce plementary experiments. At first, the IgG fraction of
a nonspecific amplification of autoantibody response to blood sera obtained from AA rats (peak of disease) was
other inflammatory mediators. Serum obtained from AA purified on a CNBr-TNF-purification column and tested
rats treated with TNF- encoding DNA vaccine (titer of for anti-TNF- neutralizing competence in an in vitro
log2 24) was tested for antibody titer to MIP-1, MCP-1, system. Figure 3A shows that these anti-TNF-Ab could
IP-10, and IL-15. All titers varied between log2 14 and effectively abolish the cytotoxic activity of TNF- on
log2 16, which is similar to titers obtained in sera from U937 human T cells (p  0.001). They were then tested
control AA rats (see Figure 1). This implies that despite for their competence to suppress AA in adoptive transfer
the CpG sequence included in these plasmids, the vac- experiments. Figure 3B shows that TNF--specific anti-
cines amplify responses in a specific manner. bodies produced in AA rats (that were not subjected to
plasmid DNA therapy) can effectively suppress ongoing
Adoptive Transfer of Autoantibodies Elicited AA (mean maximal score of 4.66  1 versus 10.3  1.5
by DNA Vaccines Suppresses Arthritis and 10  1 in control groups, p  0.01). This suggests
The beneficial effect of each vaccine could be adoptively that these antibodies can potentially be involved in the
transferred by autoantibodies that were produced in regulation of disease. To further explore this possibility,
DNA vaccinated rats (Figure 1C, p0.01 for the compar- we have looked for a way to abolish their in vivo elicita-
ison of each treated group with each of the two control tion in a specific manner. Neonatal administration of a
groups). These results, together with our previous ob- self-antigen may result in an inability to mount a signifi-
servations (Wildbaum et al., 2002a, 2000b; Youssef et cant immune response against it in adult life (i.e., neona-
al., 2000), strongly suggest that DNA vaccines amplify tal tolerance) (Gammon et al., 1986). This approach has
a regulatory response aimed to restrain the pathological recently been extended to plasmid DNA vaccines (Mor
consequences of autoimmunity. et al., 1996). We used our TNF- encoding DNA plasmid
to induce neonatal tolerance to its gene product and
studied the consequences of this abolition on the devel-Beneficial Autoimmunity Is Restricted
to Highly Selective Determinants opment and progression of AA (Figure 4). At first, we
looked for a way to obtain a moderate form of disease,To further explore the above hypothesis, we decided to
focus on one of these mediators, TNF-. This proinflam- which potentially could be aggravated. We found that
Immunity
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Figure 2. Beneficial Autoimmunity Is Restricted to Highly Selective Determinants
Rat TNF- (a 237 amino acid protein) was subjected to trypsin proteolysis followed by HPLC purification, resulting in 24 different fragments
that comprise the whole protein. Each fragment was sequence-verified, coated on an ELISA plate, and used to map the epitopes recognized
by the sera of TNF- DNA-vaccinated rats. Groups of 3 rats were subjected to active AA induction. On day 18, just before the peak of disease,
these rats were (black columns) or were not (striped columns) treated with a TNF- encoding DNA plasmid. Three days later (day 21), blood
serum from each group was tested for its ability to bind each of the different TNF- fragments described above. Results are shown as mean
of triplicates  SE.
(B) Equal amounts of IL-18 (R&D systems), TNF- (PeproTech), TRANCE, (R&D systems), MIP-1 (PeproTech), or Fas L (R&D systems) were
separated on an SDS-PAGE gel and stained by Coomassie (left) or detected by Western blotting with the sera from AA rats treated with a
TNF--encoding DNA vaccine (right). Only TNF- could be detected by the antisera, demonstrating the specificity of the vaccine-induced
autoimmune response.
under our working conditions administration of 0.2–0.4 rats). This group mounted similar levels of Ab titers to
MCP-1 or IP-10 to those measured in AA rats that weremg of MT in 100 l oil (rather than 1 mg) leads to the
development of a milder form of AA (Figure 4A). Rats that not subjected to neonatal administration of TNF- en-
coding DNA (log2 Ab titer of 8 0 each). Thus, abrogationwere subjected to a neonatal administration of TNF-
encoding DNA plasmid failed to elicit anti-TNF- Ab titer of the competence to elicit antibodies to TNF- was
specific. These experiments imply that autoantibodiesduring AA (Figure 4B, log2Ab of 14.2  0.23 in AA rats
that were not subjected to neonatal tolerance versus to TNF- contribute to the natural regulation of disease.
Replacement therapy with TNF--specific antibodies re-6.2  0.6 in those neonatally administered with TNF-
encoding DNA vaccine, b versus d, p  0.01). These versed the effect of neonatal tolerance (Figure 4C). Clini-
cal scores were verified histologically. Rats that wererats with impaired anti-TNF- responses developed an
extremely severe form of disease (Figure 4A, mean maxi- subjected to a neonatal administration of TNF- encod-
ing DNA vaccines exhibited an extremely enhanced in-mal score of 13.3  0.9 versus 5.3  0.6 in control AA
Beneficial Autoimmunity to Inflammatory Mediators
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Figure 3. TNF- Specific Autoantibodies
Produced in AA Rats Are Neutralizing and
Therapeutically Effective
Anti-TNF- antibodies were purified from the
sera of unvaccinated AA rats (endogenous
anti-TNF-), using protein-G purification of
the IgG fraction, followed by affinity purifica-
tion on a CNBr-TNF- purification column.
(A) The purified, endogenous anti-TNF- was
tested for TNF--neutralizing activity in an in
vitro system based on Wallach (1984) with
our minor modifications (Wildbaum and Karin,
1999). The TNF--dependent inhibition of
neutral red uptake of U937 cells, seen in the
absence of blocking antibody (open squares),
was blocked by purified endogenous anti-
TNF- (filled circles) but not by purified IgG
from naive Lewis rats (open circles) (100 pg/
well of each Ab, 4  104 U937 cells/well in a
total volume of 100 l). Results are shown as
mean O.D. of triplicates at 570 nm  SD.
(B) The purified endogenous anti-TNF- antibodies described above were tested for their ability to suppress ongoing AA, in an adoptive
transfer experiment. Rats with developing AA were separated, 1 day after the onset of disease, into three equally sick groups of six rats each,
that were administered, every other day, with 100 g/rat of purified endogenous anti-TNF- (filled circles), purified IgG from naive Lewis rats
(open circles), or an equal volume of PBS (open squares). Results are shown as the mean maximal score  SD. The experiment was repeated
three times with similar results and one representative experiment is shown.
flammatory process in the joints compared to control 64, range 54–78. Disease duration range was 4–12 years,
mean 7.5). All had well-established primary osteoarthri-AA rats (Figure 4Dc versus 4Db). This exacerbation of
disease could be reversed by TNF--specific autoanti- tis of either knees or knees	 hands (Heberden’s nodes),
grade 2–3 on X-rays. They were on either various NSAIDbodies (Figure 4D).
Interestingly, administration of TNF- DNA vaccine at or analgesics. None had immunosuppressive therapy.
The control group consisted of 12 healthy people (9F/4 weeks of age to rats that have been subjected to
neonatal administration of the same vaccine could par- 3M, females mean age 49, range 27–62).
Figure 5A shows that the vast majority of RA patientstially override neonatal tolerance and as a result restrain
its effect on disease severity (data not shown). This (72%), none of the control subjects, and only 20% of OA
patients developed a notable (
log2  8) Ab titer to TNF-.implies that neonatal tolerance alters an immunological
balance rather than eliminating autoreactive cells. These One-way ANOVA test (with the Bonferoni correction)
showed a significant elevation (p 0.05) in antibody titersresults are consistent with recent publications of several
groups, including ours (Forsthuber et al., 1996; Grabie in sera of RA patients compared to healthy individuals
and those suffering from OA. No significant differenceand Karin, 1999; Grabie et al., 1999; Ridge et al., 1996;
Singh et al., 1996). Taken together, the above results could be observed between the last two groups. Very high
correlation (R  0.098) was observed between the titerfurther emphasize the contribution of naturally produced
autoantibodies against proinflammatory mediators to measured in sera and synovial fluid of each RA patient
(Figure 5B). The above observations are highly interest-the regulation of autoimmunity.
ing since neutralizing TNF- suppresses human RA and
displays no effect on OA. Thus, similar to what we observedRA Patients but Not Those Suffering from OA Mount
Anti-TNF- Immunity in experimental models, during an autoimmune condi-
tion in humans, the human immune system generatesTo determine the relevance of these findings to human
autoimmunity, we have monitored the possible appear- a response that neutralizes proinflammatory mediators.
ance of anti-self-antibodies to TNF- in patients suffer-
ing from RA in comparison with those suffering from Paramount Role of TNF- in Autoimmune Arthritis
Finally, we have used the system described above toosteoarthritis, or control healthy subjects. The RA group
consisted of 22 patients (17F/5M, mean age 54, and determine whether TNF- plays a dominant role in the
pathogenesis of AA. Lewis rats were subjected to neo-range 26–73) with rheumatoid factor positive (seroposi-
tive), erosive rheumatoid arthritis, all fulfilled ACR criteria natal administration of TNF- encoding DNA plasmid
and were thus tolerized to TNF. As a result, these toler-for RA. Disease duration range was 2–28 years, mean
13.8). Patients were on various NSAID’s, low steroid ized rats could not mount autoantibody response to
neutralize endogenous TNF-. Under these conditions, re-therapy (maximum dose 10 mg/day), and had different
disease-modifying drugs like Methotrexate, Plaquenil, placement therapy with neutralizing antibodies to MCP-1
could not suppress severe AA induced by suboptimalImuran, and Solganal (gold injections). None was treated
with anti-TNF- preparations either at the time of sam- dose of adjuvant (Figure 6). These antibodies could sig-
nificantly reduce the severity of AA induced by an opti-pling or before. Out of these 22 patients, 16 had knee
effusion, which required aspiration. Blood was taken mal dose of adjuvant in control AA rats (Figure 1C). This
further substantiates the paramount role of TNF- in theon the same occasion (Figure 5B). The OA group was
composed of 10 matched patients (7F/3M, mean age regulation of autoimmune arthritis.
Immunity
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Figure 4. Selective Exclusion of Anti-TNF- Immunity Aggravates the Course of AA
During the first 24 hr after birth, groups of six Lewis rats were subjected to a single administration of 10 ng of plasmid DNA encoding TNF-
(filled squares), an empty plasmid (open squares), or PBS (filled circles). Another group was administered with the same TNF- encoding DNA
plasmid at 4 weeks of age (open triangles). At 8 weeks of age, all rats were subjected to the induction of a moderated form of AA and
monitored for the development of disease.
(A) The mean clinical score of the rats, observed in one of three experiments done under the same conditions with similar results. Results
are shown as mean clinical score  SD.
(B) At the peak of disease in control animals (day 22), sera were obtained from all rats and the TNF--specific Ab titer was determined as
follows: a, naive rats, no disease; b, AA rats; c, naive rats previously subjected to neonatal administration of TNF- encoding DNA plasmid;
d, AA rats previously subjected to neonatal administration of TNF- encoding DNA plasmid; e, AA rats subjected to “adult life” administration
of TNF- encoding DNA plasmid. Results are shown as log2Ab titer  SE of triplicates.
Beneficial Autoimmunity to Inflammatory Mediators
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Figure 6. Replacement Therapy with Anti-MCP-1 Antibodies Can-
not Override Exclusion of Anti-TNF- Immunity
During the first 24 hr after birth, four groups of six Lewis rats were
subjected to a single administration of 10 ng of plasmid DNA encod-
ing TNF-. At 8 weeks of age, these rats were subjected to the
induction of moderated AA by a suboptimal dose of CFA. Beginning
at the onset of disease, these rats were treated (100 g/rat every
other day) with neutralizing antibodies to TNF- (open squares), or
to MCP-1 (open triangles), or with IgG purified from rats that were
treated with an empty plasmid (filled squares), or were not treated
(open circles). Naive rats were also subjected to the administration
of a suboptimal form of disease (filled circles). The results of oneFigure 5. RA Patients but Not Those Suffering from OA Mount Anti-
out of two experiments done under the same conditions with similarTNF- Immunity
results are presented as mean clinical score  SD.Blood sera were obtained from 22 patients suffering from RA, 10
patients suffering from OA, and 12 healthy individuals. Synovial fluid
was also taken from all RA patients. DNA vaccines encoding proinflammatory mediators
(A) The log2Ab titer of anti-TNF- of each individual is shown. A one- have the potential capacity to augment autoimmunity.
way ANOVA test (with the Bonferoni correction) showed a significant After all, if the entire gene product of each vaccine is
elevation (p  0.05) in antibody titer determined in sera of RA pa-
produced at the site of injection it could function, at thetients compared to healthy individuals and those suffering from
protein level, to promote the inflammatory process. WeOA. No significant difference could be observed between the last
have recently shown that even though mRNA encodingtwo groups.
(B) The correlation between the Ab titer to TNF- developed in blood proinflammatory mediators is transcribed at the site of
sera and synovial fluid of the above RA patients is shown. injection, for as long as 4 weeks, the actual amount of
gene products produced there is extremely low and
is probably rapidly neutralized by autoantibodies, like
Discussion those shown to exist against TNF- (Wildbaum et al.,
2002a). According to our current study, an administra-
The current study shows that during an autoimmune tion of a DNA vaccine encoding a regulatory cytokine,
condition, the immune system mounts a beneficial auto- such as IL-4, during inflammation would not elicit anti-
antibody response to proinflammatory mediators. This IL-4 immunity. Under these conditions, the low amount
response counteracts, to a certain extent, the autoim- of IL-4 produced at the site of injection would be func-
mune pathology. This natural counteraction is illustrated tional. This may explain, in part, why administration of
in animal models of autoimmunity, and evidence is pro- DNA vaccines encoding a self-autoimmune antigen plus
vided that it occurs in the human disease rheumatoid ar- IL-4 leads to the generation of antigen-specific Th2 cells
(Garren et al., 2001).thritis.
(C) Using the same procedure, rats were subjected to TNF- encoding DNA plasmid neonatally, and to active induction of AA at 8 weeks of
age. These rats were then separated into different groups that were or were not administered (every other day beginning at the onset of
disease) with anti-TNF- Ab (IgG fraction of blood sera obtained from control AA rats, purified on a CNBr-TNF- purification column). The
mean maximal clinical score of six rats per group  SE is shown.
(D) Histological evaluation of the experiment described in (C). Joint samples from naive (a), control AA rats (b), AA rats previously subjected
to neonatal administration of TNF- encoding DNA plasmid (c), and AA rats previously subjected to neonatal administration of TNF- encoding
DNA plasmid and during disease to replacement therapy with anti-TNF- Ab (d) were subjected to histological analysis (joints from two rats
were removed 30 days after the induction of disease; 12 sections per each group were analyzed). Representative samples from each group
are presented (10). The arrowheads point to the synovial lining (b, bones; S, synovial membrane).
Immunity
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We have previously shown that during experimentally terization revealed that the vast majority of antibodies
induced autoimmune diseases, the immune system produced during the early and acute phase of disease
mounts a beneficial autoantibody response to proin- against TNF- were of the IgG2a isotype that switched
flammatory mediators (Salomon et al., 2002; Wildbaum during the chronic phase to a Th2-dependent produc-
and Karin, 1999; Wildbaum et al., 2002a, 2000b; Youssef tion of IgG1 (data not shown). This may suggest that
et al., 2000, 1998). It is an open question, however, autoantibody production to TNF- is a T-dependent re-
whether these findings that were obtained in animal sponse, though this hypothesis has yet to be proven.
models are relevant to human autoimmune diseases, Mor et al. had previously demonstrated that a neonatal
like RA. We show here (Figure 5) that patients suffering administration of a plasmid DNA vaccine would lead to
from RA but not osteoarthritis develop beneficial auto- long-term immunological tolerance to its gene product
antibody titer to TNF-. Neutralizing TNF- suppresses (Mor et al., 1996). We adopted their strategy to suppress
RA but not osteoarthritis. This suggests a novel regula- autoantibody production to TNF- (Figure 4). It should
tory mechanism in which some of the antigen-specific B be noted that the readministration of the TNF--encod-
cells that escape negative selection in the bone marrow ing DNA vaccine during established AA could partially
contribute to maintaining a checkpoint against the harmful override this state of tolerance. This suggests that regu-
functions of the immune system. Indeed, autoreactive latory mechanisms other than B cell deletion also partici-
T and B cells can be identified, in both healthy individuals pate in the regulation of neonatally induced tolerance.
and those suffering form self-destructive autoimmune There are some practical implications of finding natu-
diseases (Steinman, 1995). These self-reactive cells can rally occurring autoantibodies to TNF- in RA. This re-
be triggered either due to crossreactive responses be- sponse can be boosted with DNA vaccination. This sug-
tween microbes and self, or as a result of a bystander gests a possible use of targeted DNA vaccines toward
damage (Horwitz et al., 1998; Underhill and Ozinsky, cytokines and chemokines to which the human immune
2002; Vanderlugt and Miller, 2002; Wucherpfennig and system mounts “beneficial autoimmunity” as a potential
Strominger, 1995). We show here that under these cir- therapy for different autoimmune diseases. It may also
cumstances the immune system has also evolved to direct provide a tool for identifying important inflammatory me-
some of its anti-self-reactivity to generate a response diators in other autoimmune diseases in human. The
that restrains the destructive consequences of autoim- responses against such gene products could then be
munity. amplified to provide protective immunity.
The beneficial autoimmune response here has subtle Perhaps the most surprising finding here is the wide
features: it can distinguish proinflammatory mediators, range of anti-cytokine antibodies that are elicited during
to which it should mount beneficial anti-self-response, the disease (Figure 1A). This implies that each of these
from regulatory cytokines to which it should not. At the molecules might be important to development of the
same time, the immune system distinguishes a local full-blown syndrome of adjuvant arthritis. The hierarchal
inflammatory process (i.e., CFA immunization to hind importance of these cytokines and chemokines, and the
footpads) from an autoimmune disease, resulting from autoantibody response to them, seen in Figure 6, shows
the immunization of the same CFA to the base tail, while that in the absence of autoantibodies to TNF-, neutral-
mounting a significantly higher antibody titer to each ization of a key chemokine does not affect the course
detected proinflammatory mediator during the autoim- of disease. This further substantiates the dominant role
mune condition. The biological significance of both fea- of this cytokine in the regulation of arthritis.
tures is apparent. Turning on an autoimmune antibody
response to proinflammatory mediators is beneficial Experimental Procedures
during an autoimmune condition but could be disadvan-
Ratstageous to the host during microbial inflammation. Anti-
Female Lewis rats, approximately 6 weeks old, were purchased fromregulatory cytokine immunity could be detrimental dur-
Harlan (Jerusalem, Israel) and maintained under clean conditions ining an autoimmune conditions since it might block the
our animal facility.beneficial function of regulatory T cells that blunt the
pathological consequences of these diseases (Groux et Immunizations and Active Disease Induction
al., 1997; Wildbaum et al., 2002b). It is conceivable that a Lewis rats were immunized subcutaneously at the base of the tail
natural mechanism that includes antiregulatory cytokine with 0.1 ml of CFA (incomplete Freund’s adjuvant supplemented
with 10 mg/ml heat-killed Mycobacterium tuberculosis H37Ra in oil)immunity is a major disadvantage for the host because
(Difco Laboratories Inc., Detroit, MI) and were monitored daily forit might significantly suppress active tolerance and
clinical signs by an observer, blind to the treatment protocol. Sever-thereby increase the susceptibility to autoimmunity. How-
ity of the disease was quantified subjectively by scoring each limbever, it has never been confirmed that indeed anti-IL-4
on a scale of 0–4 to indicate the severity of peripheral joint swelling
or -IL-13 immunity does not participate in regulation of and erythema; 0  no signs of disease, 1  disease evident in a
Th2-mediated allergic diseases, such as asthma. small number of distal joints of the limb, 2  disease evident in all
The degree of subtlety in these beneficial autoimmune distal joints of the limb, 3  disease evident the entire limb, 4 
severe disease evident in the entire limb. The arthritic clinical scoreresponses is manifest in the ability to distinguish two
for each animal is the sum of the scores for all four limbs (0–16). Indifferent members of the TNF family, TNF- and FasL,
addition, the severity of disease was assessed histologically asand to produce beneficial antibody titer to the proinflam-
described below.matory TNF- and not to FasL (Figure 1A) that plays a
dual role in the regulation of T cell-mediated autoimmu- Histopathology
nity (Suvannavejh et al., 2000; Wildbaum et al., 2000a). Joints were removed, fixed with 10% buffered formalin, decalcified
The autoantibodies produced in response to each in 5% ethylenediaminetetraacetic acid in buffered formalin, embed-
ded in paraffin, and sectioned along the midline through the metatar-proinflammatory mediator were IgG. Additional charac-
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sal region (Bacha et al., 1992). Sections were stained with hematoxy- cific antibodies from sera (IgG fraction) were loaded on the column,
eluted by an acidic elution buffer (glycine pH  2.5).lin and eosin and analyzed by a histopathologist who was a blind
observer to the experimental procedure. Evaluation was based upon
the presence of an inflammatory mononuclear cell infiltrate in the Statistical Analysis
Significance of differences was examined using the Student’s t test.synovial membrane, the thickness of the synovial lining, joint space
narrowing, and periosteal new bone formation. The histological A value of p  0.05 was considered significant. The Mann-Whitney
sum of ranks test was used to evaluate the significance of differ-score was determined as follows: 0  no evidence of disease, 1 
mild lymphocytic infiltrate, 2  widespread mononuclear infiltration ences in the mean maximal clinical score. A value of p  0.05 was
considered significant.and thickening of the synovial lining, and 3  severe bone destruc-
tion, new bone formation, and destruction of the synovial lining
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